Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Anna Orlova1, Mikaela Magnusson, Tove L J Eriksson

  • 1Affibody AB, Bromma, Sweden.

Cancer Research
|April 19, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Spectrum of Non-PTPN11 Variants in Noonan Syndrome and Related RASopathies: Findings From a Russian Cohort.

Clinical genetics·2026
Same author

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal of biological engineering·2026
Same author

Assessment of the angiogenic potential of xenografted tumors by biomedical imaging techniques.

Biomedical optics express·2026
Same author

Assessing axitinib-induced differential responses in tumor vascularization and oxygenation with combined optoacoustic angiography and diffuse optical spectroscopy.

Neoplasia (New York, N.Y.)·2026
Same author

Tumour accumulation of anti-carcinoembryonic antigen affibody-albumin-binding domain fusion depends on domains' order.

International journal of biological macromolecules·2026
Same author

The Use of Glycine-Containing Peptide-Based Chelators for Labeling with <sup>99m</sup>Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1.

Molecular pharmaceutics·2026

Researchers developed a high-affinity Affibody molecule for imaging HER2-expressing cancers. This targeted protein enables clear, high-contrast visualization of tumors in vivo, improving diagnostic potential for cancer management.

Area of Science:

  • Biotechnology
  • Molecular Imaging
  • Oncology

Background:

  • Aberrant gene expression in malignant tumors produces cell-bound proteins crucial for diagnosis.
  • Targeted radionuclide imaging requires high-affinity, specific radiolabeled proteins for cancer visualization.

Purpose of the Study:

  • To develop and characterize a HER2-specific Affibody molecule for in vivo cancer imaging.
  • To enhance the affinity of a HER2-targeting Affibody molecule for improved tumor visualization.

Main Methods:

  • Affinity maturation of a HER2-specific Affibody molecule through library re-randomization.
  • Radioiodination of the affinity-matured Affibody molecule for in vivo imaging.
  • Evaluation of tumor uptake and visualization in HER2-expressing xenografts in mice.

Related Experiment Videos

Main Results:

  • A HER2-specific Affibody molecule (Z(HER2:342)) achieved 22 pmol/L affinity, a >2,200-fold increase.
  • Radioiodinated Affibody molecule enabled clear, high-contrast visualization of HER2 xenografts.
  • Tumor uptake increased 4-fold, reaching 9% injected dose per gram at 4 hours post-injection.

Conclusions:

  • Affibody molecules are a novel class of high-affinity ligands for cancer-specific targeting.
  • This Affibody molecule facilitates effective in vivo imaging of HER2-expressing tumors.
  • These findings support the potential of Affibody molecules in molecular imaging and patient management.